WHO grade 3 (anaplastic) meningioma represents the most aggressive end of the meningioma spectrum. Identifying this sub-type correctly is critical because its clinical behaviour and management differ substantially from lower-grade disease.
This protocol addresses cerebral meningioma confirmed at WHO grade 3 (anaplastic). These tumours are characterised by rapid growth, early recurrence, risk of systemic metastasis, and particular molecular features on genetic and epigenetic levels — factors that directly shape the treatment strategy.
For WHO grade 3 meningioma, the evidence-based strategy begins with a surgical step where feasible, followed by a course of radiotherapy. The complete sequence, eligibility criteria, and further details of the regimen are available in the full protocol.
DOI: 10.1093/neuonc/noab150
These tumors are characterized by rapid growth, early recurrence, risk of systemic metastasis, and particular molecular features on genetic and epigenetic levels.
Radical surgery and fractionated radiotherapy should be performed in WHO grade 3 meningiomas.
Radical surgery as feasible is recommended, followed by fractionated RT.
View source ↗